When comparing the HER2-positive status in PTs and the HER2-E intrinsic subtype in PTs, half of the tumor samples categorized as HER2-E intrinsic subtypes had HER2-positive status in the clinical pathological analyses of PTs (50%, 7/14), whereas four were ER-positive/HER2-negative, and three were triple-negative (TNBC). This evidence concerns the gene ERBB2 and neoplasm.